The research may hint at benefits, but it does not constitute proof
Por mais de um século, a aspirina ocupou silenciosamente as prateleiras das farmácias como remédio para dores cotidianas; agora, pesquisas internacionais a colocam sob nova luz, sugerindo que ela pode reduzir o risco de certos cânceres. Mas a medicina, fiel à sua prudência, lembra que uma promessa não é uma prescrição — e que o mesmo comprimido capaz de proteger pode, em outras circunstâncias, causar danos sérios. No Brasil, oncologistas pedem que a população resista à tentação de transformar esperança científica em automedicação.
- Estudos com pacientes portadores da síndrome de Lynch revelaram uma redução de 50% no risco de câncer colorretal com o uso diário de aspirina, acendendo o interesse médico mundial.
- Países como a Suécia já incorporam protocolos com aspirina em baixa dose para grupos oncológicos específicos, enquanto a mídia internacional amplifica o debate e gera expectativas na população.
- No Brasil, oncologistas como o Dr. Thiago Kloh alertam que não existem diretrizes formais que justifiquem o uso generalizado da aspirina como preventivo do câncer em pessoas saudáveis.
- O uso prolongado do medicamento traz riscos concretos e bem documentados: úlceras gástricas, hemorragias e interações perigosas com outros fármacos, especialmente em idosos polimedicados.
- A recomendação unânime dos especialistas é clara: nenhum novo regime medicamentoso deve ser iniciado sem avaliação individualizada por um médico que conheça o histórico completo do paciente.
Um analgésico centenário voltou ao centro das atenções. Pesquisas internacionais recentes sugerem que a aspirina pode ter um papel inesperado no combate ao câncer colorretal, especialmente em pacientes com predisposição genética. O estudo mais citado, conduzido por John Burn na Universidade de Newcastle, no Reino Unido, acompanhou portadores da síndrome de Lynch — condição que eleva drasticamente o risco de câncer intestinal — e constatou uma redução de 50% na incidência da doença entre aqueles que tomavam aspirina diariamente. A repercussão foi suficiente para que países como a Suécia passassem a adotar protocolos com baixas doses do medicamento para grupos oncológicos específicos.
No Brasil, porém, a cautela prevalece. O oncologista cirúrgico Dr. Thiago Kloh, professor da UNIFASE/FMP, foi enfático: as evidências disponíveis ainda não sustentam uma recomendação ampla do uso de aspirina como preventivo do câncer para a população saudável. Não há diretrizes médicas formais nesse sentido, nem um perfil claro de quem se beneficiaria de tal uso contínuo. A teoria de que as propriedades anti-inflamatórias e anticoagulantes da aspirina possam frear a disseminação de células cancerígenas é instigante, mas teoria não equivale a prova — e a medicina exige prova antes de mudar a prática.
Os riscos do uso prolongado são concretos e bem estabelecidos: úlceras estomacais, complicações hemorrágicas, incluindo acidente vascular cerebral, e interações perigosas com outros medicamentos. Para uma população envelhecida, que frequentemente já convive com múltiplas condições e tratamentos, acrescentar aspirina por razões especulativas pode gerar mais danos do que benefícios. A mensagem dos especialistas permanece a mesma de sempre: não se automedique, e não inicie nenhum novo tratamento sem consultar um médico que conheça sua história de saúde por completo.
A humble painkiller that has sat in medicine cabinets for over a century is suddenly back under the microscope. Aspirin, long known for its ability to dull headaches and fevers, has emerged from recent international research as a potential weapon against certain cancers—particularly colorectal cancer—though the medical establishment is moving cautiously, warning that the promise comes with real dangers.
The shift began when researchers started tracking patients with Lynch syndrome, a genetic condition that dramatically elevates intestinal cancer risk. In one landmark study led by John Burn at Newcastle University in the United Kingdom, patients who took aspirin daily showed a 50 percent reduction in their likelihood of developing colorectal cancer over time. The findings were striking enough that countries like Sweden have begun incorporating low-dose aspirin protocols into treatment plans for specific cancer patients, particularly those carrying genetic mutations linked to bowel tumors. The BBC Future reporting on these studies has drawn international attention to what was once considered settled science.
But in Brazil, where Petrópolis and other cities are grappling with an aging population and rising intestinal cancer rates, oncologists are pumping the brakes. Dr. Thiago Kloh, a surgical oncologist and professor at UNIFASE/FMP, was direct in an interview about the limitations of the current evidence. The research, he explained, simply does not yet justify recommending aspirin widely as a cancer preventive for healthy people. There is no formal medical guideline supporting such use, and no clear profile of patients who would benefit from taking it continuously for cancer prevention. The studies may hint at benefits, but they do not constitute the kind of consistent scientific proof needed to recommend the drug indiscriminately across the general population.
The mechanism behind aspirin's potential effect remains partially mysterious. Researchers theorize that the drug's well-known anti-inflammatory properties, combined with its ability to interfere with blood clotting, might somehow slow the spread of cancer cells through the body. But theory is not the same as proof, and proof is what medicine demands before changing practice.
What is certain, however, are aspirin's downsides. Long-term use carries documented risks: stomach ulcers, bleeding complications including hemorrhagic stroke, and dangerous interactions with other medications. Dr. Kloh emphasized these hazards, noting that the side effects are not theoretical but well-established in medical literature. For an aging population already managing multiple conditions and taking multiple drugs, adding aspirin for speculative cancer prevention could create more problems than it solves.
The conversation unfolding in Petrópolis and across Brazil reflects a broader tension in modern medicine—the gap between what laboratory findings suggest and what responsible doctors can recommend to patients. The aspirin story is not a simple yes or no. It is a reminder that even old, familiar drugs deserve scrutiny, that promising research does not automatically translate into safe practice, and that the most important medical advice remains unchanged: do not self-medicate, and do not start any new regimen without talking to a doctor who knows your full health picture.
Citas Notables
There are no consistent studies proving aspirin's effectiveness in cancer prevention. While some studies show possible benefits, there is no consistent scientific proof justifying indiscriminate use in the general population, and the medication carries real risks.— Dr. Thiago Kloh, surgical oncologist and professor at UNIFASE/FMP
There is currently no medical guideline indicating that any profile of patient would benefit from preventive, continuous aspirin use for cancer prevention.— Dr. Thiago Kloh
La Conversación del Hearth Otra perspectiva de la historia
So aspirin cuts colorectal cancer risk in half for some people. Why aren't doctors recommending it to everyone?
Because that 50 percent figure comes from a very specific group—people with Lynch syndrome, a genetic condition. The research doesn't yet show the same benefit applies to the general population. Doctors need evidence before they can responsibly tell healthy people to take a drug indefinitely.
But if it works for Lynch patients, wouldn't it be worth trying for others?
That's the logical leap everyone wants to make. But medicine doesn't work that way. What helps one group with a specific genetic profile might not help another. And aspirin isn't harmless—long-term use causes ulcers, bleeding, strokes.
So the risk outweighs the benefit right now?
For healthy people, yes. There's no proof of benefit yet, but there is proof of harm. That's an easy calculation. For someone with Lynch syndrome, a doctor might weigh it differently.
Why is this story emerging now, after aspirin has been around forever?
Better research tools, better tracking of patient outcomes over time. We're finally able to see patterns we couldn't see before. But seeing a pattern isn't the same as understanding it or knowing how to use it safely.
What would it take for doctors to change their minds?
Larger, longer studies in diverse populations. Clear guidelines from medical authorities. And honest conversations about who benefits and who gets hurt. That takes time.